Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The role for local ablative therapies in the management paradigm of oligometastatic liver disease is increasing. The evidence base supporting the use of stereotactic body radiotherapy for liver metastases has expanded rapidly over the past decade, showing high rates of local control with low associated toxicity. This review summarises the evidence base to date, discussing optimal patient selection, challenges involved with treatment delivery and optimal dose and fractionation. The reported toxicity associated with liver stereotactic body radiotherapy is presented, together with possible pitfalls in interpreting the response to treatment using standard imaging modalities. Finally, potential avenues for future research in this area are highlighted.

Original publication

DOI

10.1016/j.clon.2015.01.032

Type

Journal article

Journal

Clin Oncol (R Coll Radiol)

Publication Date

05/2015

Volume

27

Pages

307 - 315

Keywords

Ablative therapy, SABR, SBRT, liver, metastases, stereotactic, Dose Fractionation, Radiation, Humans, Liver Neoplasms, Neoplasm Metastasis, Radiosurgery